logo
episode-header-image
Apr 2023
20m 35s

Episode 234: Amar Kishan, MD, on Neoadju...

THE UROMIGOS
About this episode

In the first part of our Hollywood tour, Amar Kishan, MD, joins us to discuss his recent meta-analysis published in the Journal of Clinical Oncology on the effects of concurrent adjuvant sequencing versus neoadjuvant concurrent sequencing. Dr. Kishan also gives an overview of the added benefit that androgen deprivation therapy provides when combined with radiation therapy. Dr. Kishan is the Vice Chair of Clinical and Translational Research and Chief of GU Radiotherapy at the University of California, Los Angeles.


Up next
Yesterday
Episodio 485: ASCO GU 2026 - LITESPARK 011: Len/Belzutifan vs Cabo
En este episodio se abordan los resultados más recientes del ensayo fase 3 LITESPARK 011 (belzutifan + lenvatinib frente a cabozantinib). Brian, Tom y Bob Motzer analizan la eficacia, seguridad y las implicaciones de los resultados para la secuenciación de tratamiento. 
31m 27s
Yesterday
Episodio 484: ASCO GU 2026 - LITESPARK 022: Pembro adyuvante + Belzutifan en cáncer renal 
En esta discusión se exploran los últimos avances en el tratamiento adyuvante del cáncer de riñón, centrándose en los recientes resultados del ensayo fase 3 de belzutifan en combinación con pembrolizumab (LITESPARK-022). Se abordan los pormenores del mecanismo de acción, el desar ... Show More
36m 53s
Yesterday
Episodio 483: ASCO GU 2026 - KEYNOTE B15: EVP neoadyuvante vs Gem/Cis en cáncer de vejiga músculo-invasivo cisplatino elegible
En este episodio, Brian, Tom y Matt Galsky analizan los datos del estudio B15 sobre terapia neoadyuvante para el cáncer de vejiga músculo-invasivo cisplatino-elegible, centrándose en la eficacia de EV-Pembro en comparación con cisplatino-gemcitabina. Exploran la SLE, SG y las imp ... Show More
42m 19s
Recommended Episodes
May 2024
Highlights From the American Head and Neck Society Annual Meeting at COSM 2024
Combined Otolaryngology Spring Meetings Chair Patrick Ha, MD, and Co-Chairs Nicole C. Schmitt, MD, and Sidharth V. Puram, MD, PhD, share late-breaking research from the annual Combined Otolaryngology Spring Meetings in an interview hosted by JAMA Otolaryngology Web Editor Paul C. ... Show More
18m 51s
Jul 2023
Using Deliberate Practice to Improve Psychotherapy Results with Dr. Scott Miller
Dr. Miller's first appearance on the Psychiatry and Psychotherapy Podcast was in episode 077, "Getting Better Results from your Patients as a Psychotherapist," during which we discussed his book, Better Results. We explored the methodology behind improving outcomes in therapy thr ... Show More
1h 25m
Apr 2023
Therapy for Stage IV NSCLC Without Driver Alterations: ASCO Living Guideline Update 2023.1 Part 1
Dr. Dwight Owen is back on the ASCO Guidelines podcast, discussing the latest updates to the ASCO living guidelines for stage IV NSCLC. In Part 1, Dr. Owen presents the update for stage IV NSCLC without driver alterations. He reviews new evidence from EMPOWER-Lung3 and POSEIDON a ... Show More
11m 24s
Feb 2023
Episode 275: Anti-Racism in Medicine Series – Episode 19 – Reframing the Opioid Epidemic: Anti-Racist Praxis, Racial Health Inequities, and Harm Reduction
CPSolvers: Anti-Racism in Medicine Series  Episode 19 – Reframing the Opioid Epidemic: Anti-Racist Praxis, Racial Health Inequities, and Harm Reduction Show Notes by Alec Calac February 9, 2022 Summary: This episode highlights racialized disparities in addiction treatment. During ... Show More
1h 21m
Jun 2023
Highlights From the 2023 American Society of Clinical Oncology Annual Meeting
<p>JAMA Deputy Editor and JAMA Oncology Editor Mary (Nora) L. Disis, MD, speaks with Kimmie Ng, MD, MPH, chair of the meeting's Scientific Program Committee and associate chief of the Division of Gastrointestinal Oncology at Dana-Farber Cancer Institute.<br /> <br /> <strong>Rela ... Show More
21m 41s
Feb 2024
Therapy for Stage IV NSCLC Without Driver Alterations: ASCO Living Guideline Update 2023.3 Part 1
Dr. Jyoti Patel and Dr. Natasha Leighl discuss the latest full update to the stage IV NSCLC without driver alterations living guideline. This guideline addresses first-, second-, and subsequent-line therapy for patients according to their histology (squamous cell and nonsquamous ... Show More
9m 49s
Jul 2021
Episode 39: R-CHOP versus DA-EPOCH-R for Double-Hit Lymphoma
Alan Skarbnik (@ASkarbnik), MD, director of the lymphoma and CLL program, Novant Health (Charlotte, NC), and Aaron Goodman (@AaronGoodman33), MD, hematologist, University of California San Diego, join the show for a long-awaited debate: treating double-hit lymphoma with R-CHOP vs ... Show More
1h 6m
Jul 2022
Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations: ASCO Living Guideline (Part 2)
An interview with Dr. Ishmael Jaiyesimi from Beaumont Health Royal Oak and Oakland University William Beaumont School of Medicine in Royal Oak, MI, and Dr. Andrew Robinson from Kingston General Hospital, Queen's University in Ontario, Canada, authors on "Therapy for Stage IV Non- ... Show More
11m 59s